Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by Maciej Banach
Total Records ( 4 ) for Maciej Banach
  Maciej Banach , Dagmara Hering , Krzysztof Narkiewicz , Michal Mysliwiec , Jacek Rysz and Jolanta Malyszko
  The year 2012 has been extremely interesting concerning new findings on diagnosis, management and therapy of dyslipidaemia, hypertension and kidney disease. Looking at recent lipid disorders studies, two issues have seemed to be especially important-searching for new potent biomarkers of lipid disorders (including studies on dysfunctional High Density Lipoprotein [HDL] cholesterol, as well as subfractions/subpopulations of HDL/Low Density Lipoprotein [LDL] cholesterol) and research on new lipid disorders drugs, especially concerning proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which seem to be very potent in LDL-C lowering. Within the past year, there has been also growing clinical and research progress in hypertension management, especially concerning Resistant Hypertension (RH). In 2012, many important studies on Renal denervation (RDN), as a method of RH therapy have been published, including the ones with patients with different concomitant diseases (e.g., Chronic Kidney Disease (CKD)), as well as with longer follow-up. On the basis of the available data RDN has gained an important role in RH treatment and has recently been introduced to clinical practice. November 2012 has been critical for new nephrology data, as the most important trails were presented during American Society of Nephrology (ASN) Congress in San Diego. They concerned among others, the problems of secondary hyperparathyroidism management in CKD patients, new data on transplantations (e.g., glucocorticoid avoidance strategy), nephrocardiology (stepped pharmacotherapy algorithm vs. ultrafiltration in heart failure patients with CKD), as well as acute kidney injury and diabetic nephropathy (new data on bardoxolone methyl).
  Maciej Banach , Michael Davidson and Peter P. Toth
  Not available
  Andrzej Rynkiewicz , Barbara Cybulska , Maciej Banach , Krzysztof Filipiak , Tomasz Guzik , Barbara Idzior-Walus , Jacek Imiela , Piotr Jankowski , Longina Kłosiewicz-Latoszek , Janusz Limon , Małgorzata Myśliwiec , Grzegorz Opolski , Andrzej Steciwko , Janina Stepinska and Tomasz Zdrojewski
  Heterozygous familial hypercholesterolemia (HFH) affects on average 1 in 500 individuals in European countries, and it is estimated that HeFH in Poland may affect more than 80,000 people. Cardiovascular mortality in individuals with FH between 20 and 39 years of age is 100 times higher than in the general population. HFH is a relatively common lipid disorder, but usually still remaining undiagnosed and untreated. A very high risk of cardiovascular diseases and a shortened lifespan in patients with this condition require early diagnosis and intensive treatment. The aim of the position paper was to present the importance and scale of this problem in Poland, which has not been raised enough so far, as well as the recommendations of diagnosis, treatment and prevention methods.
  Małgorzata Mysliwiec , Mieczysław Walczak , Ewa Małecka-Tendera , Anna Dobrzanska , Barbara Cybulska , Krzysztof Filipiak , Artur Mazur , Przemysława Jarosz-Chobot , Agnieszka Szadkowska , Andrzej Rynkiewicz , Alicja Chybicka , Piotr Socha , Agnieszka Brandt , Joanna Bautembach-Minkowska , Tomasz Zdrojewski , Janusz Limon , Samuel S. Gidding and Maciej Banach
  Familial hypercholesterolemia (FH) affects on average 1 in 500 individuals in European countries, and it is estimated that FH in Poland may affect more than 80,000 people. However, in Poland, only about 20% of the population is estimated to have been diagnosed with FH, of which only a small number receive adequate treatment. FH results in more rapid development of atherosclerosis and is associated with a high risk of cardiovascular events. Atherosclerosis develops beginning in childhood in patients with FH and reaches advanced stages before clinical manifestations develop. Inadequate diagnostics and treatment of FH in Polish children suggests a need for raising the level of awareness and understanding of the condition in both society and among health professionals. These recommendations present the current epidemiological status, guidelines for diagnosing FH in Polish children and adolescents, and effective treatment options.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility